Paris, 30 May 2022 – 8.30 pm CET – Advicenne (Euronext Growth Paris ALDVI – FR0013296746), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced the launch of its new website, www.advicenne.com.
